Amgen steams ahead with EU evolocumab filing
This article was originally published in Scrip
Executive Summary
Amgen is keeping up the momentum to try and ensure evolocumab is the first PCSK9 inhibitor to market. Less than a week after its US filing, the company has submitted the cholesterol-lowering drug to the European Medicines Agency (EMA).